Skip to menu Skip to content Skip to footer
News

Second antibiotic no advantage for treating super-bug Golden Staph

13 February 2020
Decorative

A world-first clinical trial has called into question the effectiveness of using more than one antibiotic to treat the deadly ‘super-bug’, Methicillin-resistant staphylococcus aureus (MRSA) Bacteremia, commonly known as Golden Staph.

Researchers from The University of Queensland, in collaboration with global counterparts, have found using two antibiotics to treat MRSA infection provides no advantage over using a single antibiotic.

The three-year multi-centre study involved 352 patients at 27 hospitals in Australia, Singapore, Israel and New Zealand.

UQ Professor David Paterson said researchers tested whether adding a second antibiotic for seven days to a standard antibiotic treatment would lead to improved health outcomes after 90 days.

“We found no significant difference in mortality, bacteria in the blood, infection relapse or treatment failure,” Professor Paterson said.

“Furthermore, patients who received two antibiotics had a higher rate of side effects related to kidney function than those who received just one antibiotic. 

“For many years doctors have debated whether MRSA should be treated with two antibiotics or just one antibiotic.

“This trial now puts that debate to rest and will have a huge impact on how antibiotics are used for MRSA infections worldwide.

“These findings are hugely important on a number of levels – one of the most important implications of the research is how it can impact antibiotic use and the global issue of antibiotic resistance.”

MRSA is a common and very serious cause of infection that affects more than 10,000 people in Australia every year, especially women aged 60 and over.

Treating the infection can take up to several months and requires lab testing for diagnosis.

This study has been published in the journal JAMA.

Collaborating partners included the University of Melbourne, Menzies School of Health Research, UQ, Brisbane’s Royal Brisbane and Women’s Hospital and Princess Alexandra Hospital,  Cairns Hospital, Austin Health,  Concord Repatriation General Hospital, Blacktown Hospital, Royal Prince Alfred Hospital, NSW Health, Duke University, Eastern Health, Flinders Medical Centre, Footscray Hospital, , The Queen Elizabeth Hospital, Narin BAK, The Royal Adelaide Hospital, Westmead Hospital, Sydney and Wollongong Public Hospital.

Related articles

Close-up photo of a pair of hands holding a Wegovy injection pen, with the medication package on a light-coloured surface
Analysis

Would subsidising weight loss drugs make health care fairer?

GLP-1 medicines such as Ozempic, Wegovy and Mounjaro have transformed the treatment of obesity, but access to them in Australia increasingly depends on something much less medical: whether you can afford them.
20 October 2026
Woman wearing a medical mask and grey t-shirt getting a vaccination from a nurse wearing blue surgical gloves.

Vaccination has little impact on post-COVID smell and taste issues

Researchers examining whether COVID-19 vaccination affects persistent smell or taste problems after contracting the virus have found that, in most cases, it does not.
20 October 2026

Media contact

Subscribe to UQ News

Get the latest from our newsroom.